
|Articles|September 1, 2003
Limited TIMs?
Author(s)Timothy N. Troy
London -- A report published by Britain's National Prescribing Center saying that Fujisawa's Protopic (tacrolimus) and Novartis' Elidel (pimecrolimus) have only a limited role in the treatment of eczema was intended for general practitioners rather than dermatologists and refers mostly to mild cases treated in primary care settings.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














